Related Experiment Videos
Adverse drug reactions to anthelmintics
Haleh Bagheri1, Elise Simiand, Jean-Louis Montastruc
1Department of Pharmacology, Midi-Pyrenees Center of Pharmacovigilance, Faculty of Medicine, Toulouse University Hospital, Toulouse, France. bagheri@cict.fr
The Annals of Pharmacotherapy
|January 30, 2004
Summary
Adverse drug reactions (ADRs) from anthelmintics vary by drug and use. Improving ADR reporting for these commonly used medications is crucial for understanding their benefit-risk profile.
Area of Science:
- Pharmacovigilance
- Infectious Diseases
- Drug Safety
Background:
- Anthelmintics are widely used globally, yet pharmacoepidemiologic studies on their adverse drug reactions (ADRs) are scarce.
- This study addresses the lack of data on ADRs associated with various anthelmintic medications.
Purpose of the Study:
- To investigate and characterize adverse drug reactions (ADRs) associated with commonly prescribed anthelmintic drugs.
- To analyze the types and seriousness of ADRs based on drug, dosage, and indication.
Main Methods:
- A comprehensive review of spontaneous ADR reports for nine anthelmintics was conducted.
- Data from the French Pharmacovigilance Database (1985-1999) included patient demographics, ADRs, drug details, dosage, and indication.
Main Results:
- 243 cases reported 291 ADRs; serious ADRs (hematologic/hepatic) were linked to albendazole for echinococcosis/cysticercosis treatment.
- ADR profiles and seriousness varied significantly based on the specific anthelmintic and its therapeutic application.
- Low spontaneous reporting rates suggest significant underreporting of anthelmintic-induced ADRs.
Conclusions:
- Enhancing the reporting of serious or unlabeled ADRs is essential for a clearer understanding of anthelmintic benefit-risk ratios.
- Improved reporting will optimize the clinical use of anthelmintic agents.